A review of the use of modafinil for attention-deficit hyperactivity disorder

References

• Faraone SV, Biederman J, Spencer T et al. Attention-deficit/hyperactivity disorder in adults: an overview.Biol. Psychiatry48(1), 9–20 (2000).
   PubMed Web of Science ®Google Scholar
• Willoughby MT. Developmental course of ADHD symptomatology during the transition from childhood to adolescence: a review with recommendations.J. Child Psychol. Psychiatry44(1), 88–106 (2003).
   PubMed Web of Science ®Google Scholar
• Biederman J, Faraone SV, Monuteaux MC, Bober M, Cadogen E. Gender effects on attention-deficit/hyperactivity disorder in adults, revisited.Biol. Psychiatry55(7), 692–700 (2004).
   PubMed Web of Science ®Google Scholar
• Biederman J, Faraone SV, Mick E et al. Clinical correlates of ADHD in females: findings from a large group of girls ascertained from pediatric and psychiatric referral sources.J. Am. Acad. Child Adolesc. Psychiatry38(8), 966–975 (1999).
   PubMed Web of Science ®Google Scholar
• Barbaresi WJ, Katusic SK, Colligan RC et al. How common is attention-deficit/hyperactivity disorder? Incidence in a population-based birth cohort in Rochester, Minn.Arch. Pediatr. Adolesc. Med.156(3), 217–224 (2002).
   PubMedGoogle Scholar
• Faraone SV, Sergeant J, Gillberg C, Biederman J. The worldwide prevalence of ADHD: is it an American condition?World Psychiatry2(2), 104–113 (2003).
   PubMedGoogle Scholar
• Bolanos CA, Barrot M, Berton O, Wallace-Black D, Nestler EJ. Methylphenidate treatment during pre- and periadolescence alters behavioral responses to emotional stimuli at adulthood.Biol. Psychiatry54(12), 1317–1329 (2003).
   PubMed Web of Science ®Google Scholar
• Kessler RC, Adler LA, Barkley R et al. Patterns and predictors of attention-deficit/hyperactivity disorder persistence into adulthood: results from the national comorbidity survey replication.Biol. Psychiatry57(11), 1442–1451 (2005).
   PubMed Web of Science ®Google Scholar
• Biederman J, Faraone S, Milberger S et al. Predictors of persistence and remission of ADHD into adolescence: results from a four-year prospective follow-up study.J. Am. Acad. Child Adolesc. Psychiatry35(3), 343–351 (1996).
   PubMed Web of Science ®Google Scholar
• Faraone SV, Biederman J. What is the prevalence of adult ADHD? Results of a population screen of 966 adults.J. Atten. Disord.9(2), 384–391 (2005).
   PubMedGoogle Scholar
• Wilens TE. Impact of ADHD and its treatment on substance abuse in adults.J. Clin. Psychiatry65 (Suppl. 3), 38–45 (2004).
   PubMed Web of Science ®Google Scholar
• Dinn WM, Robbins NC, Harris CL. Adult attention-deficit/hyperactivity disorder: neuropsychological correlates and clinical presentation.Brain Cogn.46(1–2), 114–121 (2001).
   PubMed Web of Science ®Google Scholar
• Ossmann JM, Mulligan NW. Inhibition and attention-deficit hyperactivity disorder in adults.Am. J. Psychol.116(1), 35–50 (2003).
   PubMed Web of Science ®Google Scholar
• Walker AJ, Shores EA, Trollor JN, Lee T, Sachdev PS. Neuropsychological functioning of adults with attention-deficit hyperactivity disorder.J. Clin. Exp. Neuropsychol.22(1), 115–124 (2000).
   PubMed Web of Science ®Google Scholar
• Murphy P. Cognitive functioning in adults with attention-deficit/hyperactivity disorder.J. Atten. Disord.5(4), 203–209 (2002).
   PubMedGoogle Scholar
• Ernst M, Kimes AS, London ED et al. Neural substrates of decision making in adults with attention-deficit hyperactivity disorder.Am. J. Psychiatry160(6), 1061–1070 (2003).
   PubMed Web of Science ®Google Scholar
• Faraone SV, Spencer, T, Aleardi M, Pagano C, Biederman J. Meta-analysis of the efficacy of methylphenidate for treating adult attention-deficit/hyperactivity disorder.J. Clin. Psychopharmacol.24(1), 24–29 (2004).
   PubMed Web of Science ®Google Scholar
• Volkow ND, Swanson JM. Variables that affect the clinical use and abuse of methylphenidate in the treatment of ADHD.Am. J. Psychiatry160(11), 1909–1918 (2003).
   PubMed Web of Science ®Google Scholar
• Biederman J, Faraone SV. Attention-deficit hyperactivity disorder.Lancet366(9481), 237–248 (2005).
   PubMed Web of Science ®Google Scholar
• Rugino TA, Copley TC. Effects of modafinil in children with attention-deficit/hyperactivity disorder: an open-label study.J. Am. Acad. Child Adolesc. Psychiatry40(2), 230–235 (2001).
   PubMed Web of Science ®Google Scholar
• Rugino TA, Samsock TC. Modafinil in children with attention-deficit hyperactivity disorder.Pediatr. Neurol.29(2), 136–142 (2003).
   PubMed Web of Science ®Google Scholar
• Turner DC, Clark L, Dowson J, Robbins TW, Sahakian BJ. Modafinil improves cognition and response inhibition in adult attention-deficit/hyperactivity disorder.Biol. Psychiatry55(10), 1031–1040 (2004).
   PubMed Web of Science ®Google Scholar
• Biederman J, Swanson JM, Wigal SB et al. Efficacy and safety of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, flexible-dose study.Pediatrics116(6), E777–E784 (2005).
   PubMed Web of Science ®Google Scholar
• Jasinski DR, Kovacevic-Ristanovic R. Evaluation of the abuse liability of modafinil and other drugs for excessive daytime sleepiness associated with narcolepsy.Clin. Neuropharmacol.23(3), 149–156 (2000).
   PubMed Web of Science ®Google Scholar
• Pliszka SR. nonstimulant treatment of attention-deficit/hyperactivity disorder.CNS Spectr.8(4), 253–258 (2003).
   PubMed Web of Science ®Google Scholar
• Pataki CS, Feinberg DT, McGough JJ. New drugs for the treatment of attention-deficit/hyperactivity disorder.Expert Opin. Emerg. Drugs.9(2), 293–302 (2004).
   PubMedGoogle Scholar
• Levine L, Wang Y, Zheng Y et al. Atomoxetine vs. methylphenidate in ADHD treatment: an international pediatric trial.Eur. Neuropsychopharmacol.15(Suppl. 3), S602 (2005).
   Google Scholar
• Provigil Modafinil Datasheet. Date of first authorisation 14 October 1997 (1997).
   Google Scholar
• Jasinski DR. An evaluation of the abuse potential of modafinil using methylphenidate as a reference.J. Psychopharmacol.14(1), 53–60 (2000).
   PubMed Web of Science ®Google Scholar
• Fava M, Thase ME, DeBattista C. A multicenter, placebo-controlled study of modafinil augmentation in partial responders to selective serotonin reuptake inhibitors with persistent fatigue and sleepiness.J. Clin. Psychiatry66(1), 85–93 (2005).
   PubMed Web of Science ®Google Scholar
• Rasmussen NA, Schroder P, Olsen LR, Brodsgaard M, Unden M, Bech P. Modafinil augmentation in depressed patients with partial response to antidepressants: a pilot study on self-reported symptoms covered by the Major Depression Inventory (MDI) and the Symptom Checklist (SCL-92).Nord. J. Psychiatry59(3), 173–178 (2005).
   PubMed Web of Science ®Google Scholar
• DeBattista C, Lembke A, Solvason HB, Ghebremichael R, Poirier J. A prospective trial of modafinil as an adjunctive treatment of major depression.J. Clin. Psychopharmacol.24(1), 87–90 (2004).
   PubMed Web of Science ®Google Scholar
• Xiong GL, Christopher EJ, Goebel J. Modafinil as an alternative to methylphenidate as augmentation for depression treatment.Psychosomatics.46(6), 578–579 (2005).
   PubMedGoogle Scholar
• Saletu B, Saletu M, Grunberger J, Frey R, Zatschek I, Mader R. On the treatment of the alcoholic organic brain syndrome with an α-adrenergic agonist modafinil: double-blind, placebo-controlled clinical, psychometric and neurophysiological studies.Prog. Neuropsychopharmacol. Biol. Psychiatry14(2), 195–214 (1990).
   PubMedGoogle Scholar
• Talbot K, Stradling J, Crosby J, Hilton-Jones D. Reduction in excess daytime sleepiness by modafinil in patients with myotonic dystrophy.Neuromuscul. Disord.13(5), 357–364 (2003).
   PubMed Web of Science ®Google Scholar
• Ondo WG, Fayle R, Atassi F, Jankovic J. Modafinil for daytime somnolence in Parkinson's disease: double blind, placebo controlled parallel trial.J. Neurol. Neurosurg. Psychiatry76(12), 1636–1639 (2005).
   PubMed Web of Science ®Google Scholar
• Adler CH, Caviness JN, Hentz JG, Lind M, Tiede J. Randomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson's disease.Mov. Disord.18(3), 287–293 (2003).
   PubMed Web of Science ®Google Scholar
• Hogl B, Saletu M, Brandauer E et al. Modafinil for the treatment of daytime sleepiness in Parkinson's disease: a double-blind, randomized, crossover, placebo-controlled polygraphic trial.Sleep25(8), 905–909 (2002).
   PubMed Web of Science ®Google Scholar
• Hurst DL, Lajara-Nanson W. Use of modafinil in spastic cerebral palsy.J. Child Neurol.17(3), 169–172 (2002).
   PubMedGoogle Scholar
• Rosenberg JH, Shafor R. Fatigue in multiple sclerosis: a rational approach to evaluation and treatment.Curr. Neurol. Neurosci. Rep.5(2), 140–146 (2005).
   PubMedGoogle Scholar
• Rivera VM. Modafinil for the treatment of diminished responsiveness in a patient recovering from brain surgery.Brain Inj.19(9), 725–727 (2005).
   Google Scholar
• Turner DC, Clark L, Pomarol-Clotet E, McKenna P, Robbins TW, Sahakian BJ. Modafinil improves cognition and attentional set shifting in patients with chronic schizophrenia.Neuropsychopharmacology29(7), 1363–1373 (2004).
   PubMed Web of Science ®Google Scholar
• Yu BP, Maguire GA, Liffick TF. Modafinil for treatment of the negative symptoms of schizophrenia and antipsychotic-induced sedation.Sleep25, A503–A504 (2002).
   Google Scholar
• Spence SA, Green RD, Wilkinson ID, Hunter MD. Modafinil modulates anterior cingulate function in chronic schizophrenia.Br. J. Psychiatry187, 55–61 (2005).
   PubMedGoogle Scholar
• Sevy S, Rosenthal MH, Alvir J et al. Double-blind, placebo-controlled study of modafinil for fatigue and cognition in schizophrenia patients treated with psychotropic medications.J. Clin. Psychiatry66(7), 839–843 (2005).
   PubMed Web of Science ®Google Scholar
• Makela EH, Miller K, Cutlip WD. Three case reports of modafinil use in treating sedation induced by antipsychotic medications.J. Clin. Psychiatry64(4), 485–486 (2003).
   PubMed Web of Science ®Google Scholar
• Dackis CA, Kampman KM, Lynch KG, Pettinati HM, O'Brien CP. A double-blind, placebo-controlled trial of modafinil for cocaine dependence.Neuropsychopharmacology30(1), 205–211 (2005).
   PubMed Web of Science ®Google Scholar
• Turner DC, Robbins TW, Clark L, Aron AR, Dowson J, Sahakian BJ. Cognitive enhancing effects of modafinil in healthy volunteers.Psychopharmacology (Berl).165(3), 260–269 (2003).
   PubMed Web of Science ®Google Scholar
• Muller U, Steffenhagen N, Regenthal R, Bublak P. Effects of modafinil on working memory processes in humans.Psychopharmacology (Berl.)177(1–2), 161–169 (2004).
   PubMed Web of Science ®Google Scholar
• Randall DC, Fleck NL, Shneerson JM, File SE. The cognitive-enhancing properties of modafinil are limited in non-sleep-deprived middle-aged volunteers.Pharmacol. Biochem. Behav.77(3), 547–555 (2004).
   PubMed Web of Science ®Google Scholar
• Cephalon UK Limited. Provigil Product DataSheet Pro542. December 2004. Cephalon, Inc. West Chester (2004).
   Google Scholar
• Cephalon UK Limited. Provigil Product Monograph. PRO517/Dec02 (2002).
   Google Scholar
• Taylor FB, Russo J. Efficacy of modafinil compared to dextroamphetamine for the treatment of attention-deficit hyperactivity disorder in adults.J. Child Adolesc. Psychopharmacol.10(4), 311–320 (2000).
   PubMed Web of Science ®Google Scholar
• Lin JS, Roussel B, Akaoka H, Fort P, Debilly G, Jouvet M. Role of catecholamines in the modafinil and amphetamine induced wakefulness, a comparative pharmacological study in the cat.Brain Res.591(2), 319–326 (1992).
   PubMed Web of Science ®Google Scholar
• Lin JS, Hou Y, Jouvet M. Potential brain neuronal targets for amphetamine-, methylphenidate-, and modafinil-induced wakefulness, evidenced by c-fos immunocytochemistry in the cat.Proc. Natl. Acad. Sci. USA93(24), 14128–14133 (1996).
   PubMed Web of Science ®Google Scholar
• Ferraro L, Antonelli T, O'Connor WT, Tanganelli S, Rambert FA, Fuxe K. Modafinil: an antinarcoleptic drug with a different neurochemical profile to d-amphetamine and dopamine uptake blockers.Biol. Psychiatry42(12), 1181–1183 (1997).
   PubMed Web of Science ®Google Scholar
• Nishino S, Mao J, Sampathkumaran R, Shelton J. Increased dopaminergic transmission mediates the wake-promoting effects of CNS stimulants.Sleep Res. Online1(1), 49–61 (1998).
   PubMedGoogle Scholar
• Wisor JP, Eriksson KS. Dopaminergic-adrenergic interactions in the wake promoting mechanism of modafinil.Neuroscience132(4), 1027–1034 (2005).
   PubMed Web of Science ®Google Scholar
• Wisor JP, Nishino S, Sora I, Uhl GH, Mignot E, Edgar DM. Dopaminergic role in stimulant-induced wakefulness.J. Neurosci.21(5), 1787–1794 (2001).
   PubMed Web of Science ®Google Scholar
• Simon P, Panissaud C, Costentin J. The stimulant effect of modafinil on wakefulness is not associated with an increase in anxiety in mice. A comparison with dexamphetamine.Psychopharmacology (Berl).114(4), 597–600 (1994).
   PubMed Web of Science ®Google Scholar
• Duteil J, Rambert FA, Pessonnier J, Hermant JF, Gombert R, Assous E. Central α 1-adrenergic stimulation in relation to the behaviour stimulating effect of modafinil; studies with experimental animals.Eur. J. Pharmacol.180(1), 49–58 (1990).
   PubMed Web of Science ®Google Scholar
• Shelton J, Nishino S, Vaught J, Dement WC, Mignot E. Comparative effects of modafinil and amphetamine on daytime sleepiness and cataplexy of narcoleptic dogs.Sleep18(10), 817–826 (1995).
   PubMed Web of Science ®Google Scholar
• Akaoka H, Roussel B, Lin JS, Chouvet G, Jouvet M. Effect of modafinil and amphetamine on the rat catecholaminergic neuron activity.Neurosci. Lett.123(1), 20–22 (1991).
   PubMedGoogle Scholar
• Tanganelli S, Perez de la Mora M, Ferraro L et al. Modafinil and cortical gamma-aminobutyric acid outflow. Modulation by 5-hydroxytryptamine neurotoxins.Eur. J. Pharmacol.273(1–2), 63–71 (1995).
   PubMed Web of Science ®Google Scholar
• Ishizuka T, Sakamoto Y, Sakurai T, Yamatodani A. Modafinil increases histamine release in the anterior hypothalamus of rats.Neurosci. Lett.339(2), 143–146 (2003).
   PubMed Web of Science ®Google Scholar
• Scammell TE, Estabrooke IV, McCarthy MT et al. Hypothalamic arousal regions are activated during modafinil-induced wakefulness.J. Neurosci.20(22), 8620–8628 (2000).
   PubMed Web of Science ®Google Scholar
• Ferraro L, Fuxe K, Agnati L, Tanganelli S, Tomasini MC, Antonelli T. Modafinil enhances the increase of extracellular serotonin levels induced by the antidepressant drugs fluoxetine and imipramine: a dual probe microdialysis study in awake rat. Synapse55(4), 230–241 (2005).
   PubMedGoogle Scholar
• Rosack J. Attention-deficit/hyperactivity disorder.Psychiatric News.40(24), 23 (2005).
   Google Scholar
• Owen JS, Grasela T, Robertson P, Darwish M. Population pharmacokinetics of modafinil film-coated tablets in children and adolescents with attention deficit/hyperactivity disorder. AAPS Annual Meeting and Exposition Nov 6–10 2005, Nashville, TN, Abstract W5326 (2005).
   Google Scholar
• Robertson P Jr, Hellriegel ET. Clinical pharmacokinetic profile of modafinil.Clin. Pharmacokinet.42(2), 123–137 (2003).
   PubMed Web of Science ®Google Scholar
• Wong YN, Simcoe D, Hartman LN et al. A double-blind, placebo-controlled, ascending-dose evaluation of the pharmacokinetics and tolerability of modafinil tablets in healthy male volunteers.J. Clin. Pharmacol.39(1), 30–40 (1999).
   PubMed Web of Science ®Google Scholar
• Wong YN, King SP, Simcoe D et al. Open-label, single-dose pharmacokinetic study of modafinil tablets: influence of age and gender in normal subjects.J. Clin. Pharmacol.39(3), 281–288 (1999).
   PubMed Web of Science ®Google Scholar
• Greenhill LL, Biederman J, Boellner S, Rugino TA, Sangal RB, Swanson JM. Modafinil film-coated tablets significantly improve symptoms on ADHD Rating Scale-IV School and Home and overall clinical condition in children and adolescents with attention-deficit/hyperactivity disorder. NCDEU 45th Annual Meeting Boca Raton, Florida, USA Session I-88 (2005).
   Google Scholar
• Swanson JM, Greenhill LL, Lopez FA et al. Modafinil Film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, fixed-dose study followed by abrupt discontinuation.J. Clin. Psychiatry67(1), 137–147 (2006).
   PubMed Web of Science ®Google Scholar
• Swanson JM, Greenhill LL, Lopez FA, Sedillo A, Biederman J. Modafinil film-coated tablets demonstrate early efficacy in pediatric attention-deficit/hyperactivity disorder and were not associated with withdrawal or discontinuation syndrome. NCDEU 45th Annual Meeting Boca Raton, Florida June 6–9, 2005, Session I-98 (2005).
   Google Scholar
• Biederman J, Swanson JM, Wigal SB, Kratochvil CJ, Boellner SW, Greenhill LL. Safety and efficacy of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder. NCDEU 45th Annual Meeting Boca Raton, Florida, USA June 6–9, 2005, Session I-99 (2005).
   Google Scholar
• Biederman J, Swanson JM, Lopez FA. Modafinil improves ADHD symptoms in children in a randomized, double-blind, placebo-controlled study. Annual Meeting of the American Psychiatric Association, San Francisco, CA, USA May 17–22 2003. Syllabus and scientific proceedings in summary form Abstract no. 36 (2003).
   Google Scholar
• Biederman J, Swanson JM, Boellner SW, Lopez FA. Modafinil as therapy for ADHD in children: a 4-week, double-blind, placebo-controlled study.Eur. Neuropsychopharmacol.14(Suppl. 3), S364 (2004).
   Google Scholar
• Swanson JM, Biederman J, Boellner SW, Lopez FA. Modafinil as therapy for ADHD in children: a 4-week double-blind, placebo-controlled study.J. Psychopharmacol.18(3), A53 (2004).
   Google Scholar
• Swanson JM, Greenhill LL, Biederman J. Modafinil in children with ADHD: a randomized, placebo-controlled study. Annual Meeting of the American Psychiatric Association, San Francisco, CA, USA May 17–22 2003. Syllabus and scientific proceedings in summary form Abstract no. 44 (2003).
   Google Scholar
• Swanson JM, Biederman J, Boellner SW, Earl C, Lopez FA. Modafinil as therapy for ADHD in children: an 8-week, open-label study.J. Child Adolesc. Psychopharmacol. (NCDEU Abstracts). 14(4), 512–513 (2004).
   Google Scholar
• Freeman JL, Risser MR, Ware JC et al. The effects of modafinil on simulated driving performance in ADHD subjects compared to controls (063.C).Sleep25, A46 (2002).
   Google Scholar
• Norton J. Use of modafinil in attention-deficit/hyperactivity disorder.Primary Psychiatry9(9), 48–49 (2002).
   Google Scholar
• DuPaul GJ, Power TJ, Anastopoulos AD, Reid R.ADHD Rating Scale-IV: Checklists, Norms, and Clinical Interpretation. Vol. Guilford Press New York, NY, USA (1998).
   Google Scholar
• Turner DC, Blackwell AD, Dowson JH, McLean A, Sahakian BJ. Neurocognitive effects of methylphenidate in adult attention-deficit/hyperactivity disorder.Psychopharmacology (Berl.)178(2–3), 286–295 (2005).
   PubMed Web of Science ®Google Scholar
• Mehta MA, Goodyer IM, Sahakian BJ. Methylphenidate improves working memory and set-shifting in AD/HD: relationships to baseline memory capacity.J. Child Psychol. Psychiatry45(2), 293–305 (2004).
   PubMed Web of Science ®Google Scholar
• Aron AR, Dowson JH, Sahakian BJ, Robbins TW. Methylphenidate improves response inhibition in adults with attention-deficit/hyperactivity disorder.Biol. Psychiatry54(12), 1465–1468 (2003).
   PubMed Web of Science ®Google Scholar
• Stahl SM. Awakening to the psychopharmacology of sleep and arousal: novel neurotransmitters and wake-promoting drugs.J. Clin. Psychiatry63(6), 467–468 (2002).
   PubMedGoogle Scholar
• Stahl SM. Psychopharmacology of wakefulness: pathways and neurotransmitters.J. Clin. Psychiatry63(7), 551–552 (2002).
   PubMedGoogle Scholar
• Swanson JM. Role of executive function in ADHD.J. Clin. Psychiatry64 (Suppl. 14), 35–39 (2003).
   PubMedGoogle Scholar
• Myrick H, Malcolm R, Taylor B, LaRowe S. Modafinil: preclinical, clinical, and post-marketing surveillance–a review of abuse liability issues.Ann. Clin. Psychiatry16(2), 101–109 (2004).
   PubMedGoogle Scholar
• Stoops WW, Lile JA, Fillmore MT, Glaser PE, Rush, CR. Reinforcing effects of modafinil: influence of dose and behavioral demands following drug administration.Psychopharmacology (Berl.)182(1), 186–193 (2005).
   PubMed Web of Science ®Google Scholar
• Narendran R, Young CM, Valenti AM, Nickolova MK, Pristach CA. Is psychosis exacerbated by modafinil?Arch. Gen. Psychiatry59(3), 292–293 (2002).
   Google Scholar
• Mariani JJ, Hart CL. Psychosis associated with modafinil and shift work.Am. J. Psychiatry162(10), 1983 (2005).
   PubMed Web of Science ®Google Scholar